NovoCure Ltd NVCR
NovoCure Ltd (Nasdaq: NVCR) is an oncology drug developer. Its lead program, METIS (Optune Mya), is in Phase 3 for brain metastases from non-small cell lung cancer. Its next catalyst on record is METIS (Optune Mya): PMA application decision (FDA) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: METIS (Optune Mya) — PMA application decision (FDA) (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Optune Gio | newly diagnosed glioblastoma (GBM) | device-combination | Approved |
| Optune Gio | recurrent glioblastoma (GBM) | device-combination | Approved |
| Optune Lua | metastatic non-small cell lung cancer (NSCLC) | device-combination | Approved |
| Optune Lua | malignant pleural mesothelioma (MPM) | device-combination | Approved |
| Optune Pax | locally advanced pancreatic cancer | device-combination | Approved |
| METIS (Optune Mya) | brain metastases from NSCLC | device-combination | Phase 3 |
| KEYNOTE D58 | newly diagnosed glioblastoma (GBM) | device-combination | Phase 3 |
| LUNAR-2 | non-small cell lung cancer (NSCLC) | device-combination | Phase 3 |
| PANOVA-4 | metastatic pancreatic cancer | device-combination | Phase 2 |
| Verastem collaboration | locally advanced pancreatic cancer | device-combination | Phase 1 |
Recent results and decisions
- Oct 1, 2026approval Japan's Ministry of Health, Labour and Welfare approved Optune Pax for the treatment of unresectable locally advanced pancreatic cancer.
Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
Filing - approval Optune Pax approved by Japan's Ministry of Health, Labour and Welfare for the treatment of locally advanced pancreatic cancer.
Optune Pax received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
Filing - Jun 18, 2026missed TRIDENT missed primary endpoint: median OS 17.7 vs 17.5 months, early-start vs maintenance-start TTFields (HR 0.953, p=0.519).
The trial did not demonstrate a statistically significant improvement in the primary endpoint of overall survival for the Early Start Arm compared to the Maintenance Start Arm.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.